Table 3.

Analysis of factors related to the treatment time of pembrolizumab in died patients

Factors		< median duration (N = 907)	≥median duration (N = 920)
Top 9 Regimen	Pembrolizumab	241 (26.6%)	404 (43.9%)
	Other	234 (25.8%)	116 (12.6%)
	Lenvatinib; Pembrolizumab	185 (20.4%)	196 (21.3%)
	Carboplatin; Pembrolizumab; Pemetrexed	66 (7.3%)	71 (7.7%)
	Carboplatin; Pembrolizumab; Taxane	57 (6.3%)	25 (2.7%)
	Axitinib; Pembrolizumab	14 (1.5%)	19 (2.1%)
	Pembrolizumab; Pemetrexed	7 (0.8%)	21 (2.3%)
	Cisplatin; Pembrolizumab; Pemetrexed	17 (1.9%)	5 (0.5%)
	Pembrolizumab; Taxane	86 (9.5%)	63 (6.8%)
Ingredient counts	1	241 (26.6%)	403 (43.8%)
	2	270 (29.8%)	290 (31.5%)
	3	230 (25.4%)	154 (16.7%)
	4	74 (8.2%)	29 (3.2%)
	5	42 (4.6%)	21 (2.3%)
Sex	Male	537 (59.2%)	523 (56.8%)
	Female	364 (40.1%)	351 (38.2%)
Case priority	Non-Expedited	101 (11.1%)	133 (14.5%)
	Expedited	804 (88.6%)	777 (84.5%)
Age group	< median age	466 (51.4%)	463 (50.3%)
	≥median age	441 (48.6%)	457 (49.7%)
Cancer related diagnosis	Cervix Cancer	327 (36.1%)	265 (28.8%)
	Cholangiocarcinoma	15 (1.7%)	18 (2%)
	Colorectal Cancer	70 (7.7%)	75 (8.2%)
	Endometrial Cancer	33 (3.6%)	30 (3.3%)
	Head And Neck Cancer	37 (4.1%)	83 (9%)
	Malignancy	24 (2.6%)	131 (14.2%)
	Melanoma	254 (28%)	182 (19.8%)
	Non-Small Cell Lung Cancer	87 (9.6%)	98 (10.7%)
	Renal Cancer	60 (6.6%)	37 (4%)
Reporter type	Consumer	57 (6.3%)	53 (5.8%)
	Healthcare Professional	848 (93.5%)	867 (94.2%)

Note: Other in Top 9 Regimen includes a variety of combination therapies that are less commonly used but still reported. Ingredient counts represent the number of drugs in the regimen (1 = single-drug, up to 5 = five-drug combinations). The range of Ingredient counts differs from Table 1 as Table 3 focuses on treatment duration subgroups, where regimens with > 5 components were rare